Insights Into the First Psychedelic-Assisted Therapy Guidelines With Hadas Alterman

As technological change revolutionizes medicine and healthcare, how do we ensure that no-one, particularly members of vulnerable groups, get left behind?

This is the question that companies like MindMed (MNMD, MMED) , Johnson and Johnson (JNJ), and Pfizer(PFE) , as well as government organizations like the FDA, and universities like Johns Hopkins are trying to answer through collaborating with each other in a forum called The Digital Health Measurement Collaborative Community, or DATAcc.

Useful links:

https://datacc.dimesociety.org/

https://thecannabisstock.com/2021/08/03/mindmed-joins-digital-medicine-society-to-improve-health-outcomes-and-equity-using-technology/

https://www.prnewswire.com/news-releases/healthcare-leaders-collaborate-on-digital-inclusion-initiatives-301341678.html

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #JNJ #Pfizer

Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. This segment is entitled “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” for a reason. The News we present will have major implications Psychedelic Stocks like MindMed (MMED /MMEDF/ MMQ), Compass Pathways (CMPS) and more.

In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

1. The Effects of Treating Depression with Psilocybin
2. Taking Psychedelics in a Ritual Setting
3. Microdosing study

After covering the pertinent aspects of these studies, we’ll take a look at Americans’ ability to buy Horizons’ ETF and finally we’ll give you some updates on some decriminalization efforts.

So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel
​…
​Timestamps:
0:00​ – Intro
1:24 – Effects of Treating Depression with Psilocybin
4:03 – Effects of Taking Psychedelics in A Ritual Setting
7:23 – Exploring the relationship between microdosing, personality & emotional insight
9:36 – Americans May be able to invest in Horizon’s ETF
11:42 – Progress on California’s bill that would LEGALIZE Possession of Psychedelics
12:57 – Massachusetts Approves Psychedelics Decimalization

General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​​​ ​#psychedelics​​​​ #shroomboom

MindMed has officially been added to the NASDAQ Global Market.
On April 22nd, MindMed filed an 8-A12B with the SEC which ultimately allowed it to uplist to the NASDAQ. For NEO owners, the ticker symbol will remain MMED, for OTC owners, it’ll change to MNMD.

On 23rd of April, MindMed announced that as onf April 27th MindMed will be trading as MNMD on the NASDAQ. This means that MindMed was able to meet financial and listing requirements. Typically when securities get listed on major stock exchanges, they are highly traded and prices higher than those that trade OTC. Being able to uplist and trade on an exchange such as the NASDAQ will provide MindMed exposure and visibility to a larger market which might, in the short term, 2, 3 or 4x MindMed’s stock price as more people buy the stock due to FOMO. This happened when Compass Pathways IPOed which almost 4xed its share price within a few days from $17 to $60 before CMPS dropped back down to $33.

Where does MindMed go from here on? MMEDF is just at the beginning of their long-term growth trajectory. Some investors might feel inclined to take profits, which is absolutely understandable. However, like I’ve been saying in the majority of my MindMed episodes or any psychedelic stock videos, the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MindMedNasdaq #MindMedstock